

Certificate of analysis

SFC866-03-05

Operator: Jane Vowles Date: 08/09/2015

Supervisor: Sally Cowley Date: 08/05/2017

Signature: SA Cousley


Source of fibroblasts and reprogramming information

- SF866 from Oxford University Hospitals
- Reprogrammed at UOXF JMSCF
- Reprogrammed on 02/10/2014 at passage 4
- Cytotune v2 WP3 SOP10


Viability post-thaw and Morphology according to SOP19 passage 17

- Cell count immediately post-thaw 2.7 x 10⁶
- Viability immediately post-thaw 83%
- Photo post-thaw (scale bar = 100μm):

80% plated 24 hour post thaw 24 hour




20% plated day 4 post thaw



Sendai clearance: according to WP3 SOP15 undetectable at passage 17





SFC866-03-05

SFC069-03-01

SFC139-03-06

SFC843-03-09

+ control

Product sizes: SeV 181bp; KOS 528bp; SeV-Klf 410bp; SeV-Myc 532bp; Actin 623bp

Mycoplasma Test: According to MycoAlert Lonza LT07-318 undetectable at passage 17

Sample	Clone	Passage number	Initial	Reading 1	Reading 2	Ratio/Status
+ve control				7.64	199.10	26.07
-ve control				9.31	0.60	0.06
15	SFC866-03-05	p17	JV	3.21	0.96	0.30

Results mean


Ratio 0 - 0.999 negative for mycoplasma

Ratio 1 – 1.3 Borderline Result (retest required)


Ratio above 1.3 positive for mycoplasma

Flow cytometric analysis according to WP3 SOP 20 and 21 passage p17

Tra-1-60:



NANOG:



SNP analysis according to WP3 SOP Preparation of DNA and RNA samples for Illumina arrays

- Passage 17
- Identity to parent fibroblasts confirmed
- Karyotype abnormalities: none detected
- For details and raw data see StemDB